Sarepta Therapeutics (SRPT) Other Operating Expenses (2016 - 2026)

Sarepta Therapeutics has reported Other Operating Expenses for 11 years, with the latest figure at $150.1 million in Q2 2026.

• On a quarterly basis, Other Operating Expenses fell 2.04% year-over-year to $150.1 million in Q2 2026; TTM through Jun 2026 was $810.4 million, a 178.11% increase from a year earlier, with the FY2023 full-year figure at $102.0 million, changed N/A from the prior year.
• Other Operating Expenses was $150.1 million for Q2 2026 at Sarepta Therapeutics, up from $109.5 million in the prior quarter.
• The five-year high for Other Operating Expenses was $399.4 million in Q4 2025, with the low at $31.6 million in Q1 2022.
• Average Other Operating Expenses over 5 years is $132.2 million, with a median of $123.8 million recorded in 2025.
• The sharpest annual moves came in 2025 and 2026: Other Operating Expenses surged 170.06% in 2025, then retreated 20.78% in 2026.
• Over 5 years, Other Operating Expenses stood at $31.6 million in 2022, then surged by 222.57% to $102.0 million in 2023, then sank by 49.84% to $51.2 million in 2024, then surged by 680.66% to $399.4 million in 2025, then plunged by 62.42% to $150.1 million in 2026.
• The last three Other Operating Expenses figures came in at $150.1 million (Q2 2026), $109.5 million (Q1 2026), and $399.4 million (Q4 2025), per Business Quant data.